Wu SX, et al. - The efficacy of extended nodal irradiation (ENI) and/or erlotinib was assessed in patients with histologically confirmed locally advanced oesophageal squamous cell cancer (ESCC) or medically inoperable disease. Significantly improved 2-year overall survival was achieved with radiotherapy adoption of ENI with two cycles of concurrent TP chemotherapy (paclitaxel 135 mg/m² day 1 and cisplatin 20 mg/m² days 1–3, every 4 weeks) plus erlotinib (150 mg per day during chemoradiotherapy), compared with radiotherapy adoption of conventional field irradiation (CFI) with two cycles of concurrent TP. Overall, the standard of care for inoperable ESCC might be improved with the employment of chemoradiotherapy with ENI and erlotinib. Adopting ENI alone in concurrent chemoradiotherapy for ESCC patients was recommended.